FDA approves first injectable PrEP medication to lower HIV risk
The US Food and Drug Administration has approved the first injectable medication for pre-exposure prophylaxis (PrEP) to lower the risk of getting HIV through sex, it announced Monday.
ViiV Healthcare Reports Positive Phase III Study Results
ViiV Healthcare Reports Positive Phase III Study Results Of Investigational, Long-Acting, Injectable HIV-treatment Regimen Administered Every Two Months
Gilead’s New Capsid Inhibitor in Early Trials
Gilead’s new capsid inhibitor GS-6207 has started its phase 1b trial with the potential for 3 month dosing. The capsid inhibitor is currently being dosed by a subcutaneous injection but Gilead is attempting to develop a oral formulation of the antiretroviral.
Stem Cell Transplants Leads To Likely Cured HIV Patients
At the 2019 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, a second case of an HIV positive adult cleared of the HIV virus after he received a bone marrow transplant from an HIV resistant donor was presented.
The DISCOVER Trial, a Phase 3 Study Shows Results In Descovy (TAF/FTC) As An Effective Alternative To Truvada (TDF/FTC).
The DISCOVER trial was presented at the 2019 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.